Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (SOPH) is a leader in AI-powered genomic analysis, enabling data-driven healthcare through its cloud-native SOPHiA DDM™ Platform. This page aggregates official company news and press releases, providing stakeholders with timely updates on advancements in precision medicine.
Access curated information on financial results, strategic partnerships, and technology innovations that shape the future of clinical diagnostics. Track developments in oncology solutions, regulatory milestones, and research collaborations across their global network of 1,000+ healthcare institutions.
Our repository includes updates on:
- FDA-cleared genomic profiling tools
- AI-driven diagnostic platform enhancements
- Cross-industry research initiatives in rare diseases
- Operational expansions and executive appointments
Bookmark this page for streamlined access to verified SOPHiA GENETICS updates, combining Swiss precision with cutting-edge analytics to transform patient care worldwide.
SOPHiA GENETICS (Nasdaq: SOPH) announced that Instituto Mário Penna is now utilizing its SOPHiA DDM™ Platform. This Brazilian oncology center, located in Belo Horizonte, will use the platform to enhance its research and testing for blood cancers. The SOPHiA DDM™ Platform employs next-generation sequencing (NGS) to accurately target key variants from various sample types, aiding in timely and precise detection.
The Instituto Mário Penna, a major oncology service provider in Brazil, offers comprehensive cancer care including in-patient, out-patient, chemotherapy, radiation treatments, clinical laboratory analysis, and surgery. The integration of SOPHiA DDM™ aims to improve on-site diagnostic capabilities and support data-driven treatment decisions.
Blood cancers are the fifth most common type of cancer globally, and the institute's adoption of this AI-based technology reflects a commitment to advancing healthcare in Brazil.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that the Klinikum Klagenfurt am Wörthersee, Austria's third-largest hospital, has implemented the SOPHiA DDM™ Platform. This technology aims to enhance the hospital's next-generation sequencing (NGS) testing and analytical capabilities for both solid tumors and blood cancers. It will assist in providing fast and accurate genomic analysis, aiding data-driven treatment decisions. The hospital's Institute for Laboratory Diagnostics and Microbiology (ILM) serves over half a million patients annually. The platform is expected to streamline data processing, offering reliable insights while conserving resources. This collaboration is set to improve precision medicine and molecular diagnostics at one of Austria's largest laboratories.
SOPHiA GENETICS, a cloud-native software company, reported Q1 2024 results with a 13% revenue growth to $15.8 million. Gross margins were 65.9% reported and 70.5% adjusted. Operating loss improved by 3% reported and 13% adjusted year-over-year. The company reaffirmed guidance: revenue growth of 25-30%, adjusted gross margin of 72.5-72.7%, and adjusted operating loss of $45-50 million. SOPHiA GENETICS signed debt financing for up to $50 million with Perceptive Advisors to accelerate growth. The company aims to onboard new customers and expand its Liquid Biopsy offering, MSK-ACCESS® powered with SOPHiA DDM™.
SOPHiA GENETICS, a cloud-native software company in data-driven medicine, will present at the 2024 RBC Capital Markets Global Healthcare Conference. Chief Financial Officer and Chief Operating Officer, Ross Muken, will speak on May 14, 2024, in New York City.